Northwest Pathology announced that with its earlier acquisition of Avero Diagnostics in 2021, the company has adopted the Avero Diagnostics name for the combined business and service lines of Northwest Pathology, Northwest Laboratory, and Avero Diagnostics.
The integration of both companies expands Avero’s test offerings in anatomic, clinical, and molecular pathology and brings expertise to healthcare providers. The increased operational scale and further diversified product portfolio brings women’s health, subspecialty pathology services, and routine testing in chemistry, coagulation, hematology, and microbiology under one source of service for the company’s national physician base.
“The integration of our companies will continue to take place over the next several months, and during this time our clients and their patients will continue to receive the same high quality diagnostic services they have come to expect from us. Going forward we are committed to providing innovative pathology and diagnostic testing services to the market and we are confident this transition furthers the interests of our customers and our employees,” says Matt Watson, CEO of Avero.
In addition to expanding the company’s footprint nationwide, Avero is focused on growing their national payer coverage, allowing the company to provide superior laboratory services to more physician and patient communities.